Australia markets open in 3 hours 33 minutes

Royalty Pharma plc (RPD.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
26.19-0.10 (-0.38%)
At close: 08:14AM CEST
Full screen
Previous close26.29
Open26.19
Bid25.88 x N/A
Ask25.99 x N/A
Day's range26.19 - 26.19
52-week range24.58 - 31.33
Volume100
Avg. volume1
Market cap15.479B
Beta (5Y monthly)0.47
PE ratio (TTM)15.87
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.79 (3.01%)
Ex-dividend date16 May 2024
1y target estN/A
  • GlobeNewswire

    Royalty Pharma to Present at Upcoming Investor Conferences

    NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcast

  • GlobeNewswire

    Royalty Pharma Reports First Quarter 2024 Results

    Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We con

  • GlobeNewswire

    Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

    Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIR